Hematological Malignancies clinical trials

Explore recruiting hematological malignancies clinical trials.

Recruiting hematological malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hematological Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib

Sweden, Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.

France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

DK-CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19 positive hematological malignancies (DAN-CART 1901)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Spain, Netherlands, France, Germany, Austria, Belgium +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

France, Spain, Germany, Denmark, Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol D

Netherlands, Denmark, Finland, Germany, Italy, Spain +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Hematological Malignancies trials by city

Hematological Malignancies in Toronto Hematological Malignancies in Vancouver Hematological Malignancies in Montreal Hematological Malignancies in Calgary Hematological Malignancies in Edmonton Hematological Malignancies in Ottawa Hematological Malignancies in Winnipeg Hematological Malignancies in Quebec City Hematological Malignancies in Hamilton Hematological Malignancies in Kitchener Hematological Malignancies in London Hematological Malignancies in Halifax Hematological Malignancies in New York Hematological Malignancies in Los Angeles Hematological Malignancies in Chicago Hematological Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease